Pharma teachers faking profiles at multiple institutions, face being blacklisted

New Delhi: In what has alarmed the government, the Pharmacy Council of India (PCI) has found widespread data faking on the government’s DIGI-PHARMed portal for teachers.

As many as 45,355 cases of duplicate or invalid profile details have been registered on the portal.

There are more than 42,000 pharmacy colleges in India with around 11.2 million pharmacists being registered with the council.

Pharmacists are at the forefront of healthcare, often serving as the first point of contact for individuals seeking health advice or primary care. Their roles extend far beyond merely dispensing medications.

In a recent meeting, the pharmacy education regulator was made aware about many pharmacists creating fake profiles using the same Aadhaar or PAN number, and working as faculty in multiple institutions.

Taking cognizance of this fraudulent activity, the council has decided to blacklist these fake faculty and debar them permanently if found guilty a second time.

“Council has analyzed that many pharmacists have created duplicate profiles with the same Aadhaar number or PAN number. In addition to this, all these duplicate profiles on a single Aadhaar number were found working as a faculty in different institutions,” said Anil Mittal, registrar-cum-secretary, PCI, in a communication to the registered pharmacists, state pharmacy councils and approved pharmacy institutions.

The council said that these pharmacists have entered invalid/fake Aadhaar or PAN card details during the registration on DIGI-PHARMed Portal, including Aadhaar numbers having more or less than 12 digits.

Related Posts

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

Bengaluru: In a major breakthrough in the illegal pharmaceutical network operating in Karnataka, investigators from the Special Investigation Team (SIT) raided Krupa Health Care at Minerva Circle, seizing a cache…

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

Lundbeck, a biopharmaceutical company focusing exclusively on brain health, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to asedebart (Lu AG13909), Lundbeck’s novel…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched